Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking

The kidneys are a pair of important organs that excretes endogenous waste and exogenous biological agents from the body. Numerous transporters are involved in the excretion process. The levels of these transporters could affect the pharmacokinetics of many drugs, such as organic anion drugs, organic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wei Zou, Birui Shi, Ting Zeng, Yan Zhang, Baolin Huang, Bo Ouyang, Zheng Cai, Menghua Liu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	renal drug transporters species sex-genders ages molecular docking disease status Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/a37bc5c398774634bb6bc38a1ff5d9b4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a37bc5c398774634bb6bc38a1ff5d9b4
record_format	dspace
spelling	oai:doaj.org-article:a37bc5c398774634bb6bc38a1ff5d9b42021-12-01T12:31:18ZDrug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking1663-981210.3389/fphar.2021.746208https://doaj.org/article/a37bc5c398774634bb6bc38a1ff5d9b42021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.746208/fullhttps://doaj.org/toc/1663-9812The kidneys are a pair of important organs that excretes endogenous waste and exogenous biological agents from the body. Numerous transporters are involved in the excretion process. The levels of these transporters could affect the pharmacokinetics of many drugs, such as organic anion drugs, organic cationic drugs, and peptide drugs. Eleven drug transporters in the kidney (OAT1, OAT3, OATP4C1, OCT2, MDR1, BCRP, MATE1, MATE2-K, OAT4, MRP2, and MRP4) have become necessary research items in the development of innovative drugs. However, the levels of these transporters vary between different species, sex-genders, ages, and disease statuses, which may lead to different pharmacokinetics of drugs. Here, we review the differences of the important transports in the mentioned conditions, in order to help clinicians to improve clinical prescriptions for patients. To predict drug-drug interactions (DDIs) caused by renal drug transporters, the molecular docking method is used for rapid screening of substrates or inhibitors of the drug transporters. Here, we review a large number of natural products that represent potential substrates and/or inhibitors of transporters by the molecular docking method.Wei ZouBirui ShiTing ZengYan ZhangBaolin HuangBo OuyangZheng CaiZheng CaiMenghua LiuMenghua LiuFrontiers Media S.A.articlerenal drug transportersspeciessex-gendersagesmolecular dockingdisease statusTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	renal drug transporters species sex-genders ages molecular docking disease status Therapeutics. Pharmacology RM1-950
spellingShingle	renal drug transporters species sex-genders ages molecular docking disease status Therapeutics. Pharmacology RM1-950 Wei Zou Birui Shi Ting Zeng Yan Zhang Baolin Huang Bo Ouyang Zheng Cai Zheng Cai Menghua Liu Menghua Liu Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking
description	The kidneys are a pair of important organs that excretes endogenous waste and exogenous biological agents from the body. Numerous transporters are involved in the excretion process. The levels of these transporters could affect the pharmacokinetics of many drugs, such as organic anion drugs, organic cationic drugs, and peptide drugs. Eleven drug transporters in the kidney (OAT1, OAT3, OATP4C1, OCT2, MDR1, BCRP, MATE1, MATE2-K, OAT4, MRP2, and MRP4) have become necessary research items in the development of innovative drugs. However, the levels of these transporters vary between different species, sex-genders, ages, and disease statuses, which may lead to different pharmacokinetics of drugs. Here, we review the differences of the important transports in the mentioned conditions, in order to help clinicians to improve clinical prescriptions for patients. To predict drug-drug interactions (DDIs) caused by renal drug transporters, the molecular docking method is used for rapid screening of substrates or inhibitors of the drug transporters. Here, we review a large number of natural products that represent potential substrates and/or inhibitors of transporters by the molecular docking method.
format	article
author	Wei Zou Birui Shi Ting Zeng Yan Zhang Baolin Huang Bo Ouyang Zheng Cai Zheng Cai Menghua Liu Menghua Liu
author_facet	Wei Zou Birui Shi Ting Zeng Yan Zhang Baolin Huang Bo Ouyang Zheng Cai Zheng Cai Menghua Liu Menghua Liu
author_sort	Wei Zou
title	Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking
title_short	Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking
title_full	Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking
title_fullStr	Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking
title_full_unstemmed	Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking
title_sort	drug transporters in the kidney: perspectives on species differences, disease status, and molecular docking
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/a37bc5c398774634bb6bc38a1ff5d9b4
work_keys_str_mv	AT weizou drugtransportersinthekidneyperspectivesonspeciesdifferencesdiseasestatusandmoleculardocking AT biruishi drugtransportersinthekidneyperspectivesonspeciesdifferencesdiseasestatusandmoleculardocking AT tingzeng drugtransportersinthekidneyperspectivesonspeciesdifferencesdiseasestatusandmoleculardocking AT yanzhang drugtransportersinthekidneyperspectivesonspeciesdifferencesdiseasestatusandmoleculardocking AT baolinhuang drugtransportersinthekidneyperspectivesonspeciesdifferencesdiseasestatusandmoleculardocking AT boouyang drugtransportersinthekidneyperspectivesonspeciesdifferencesdiseasestatusandmoleculardocking AT zhengcai drugtransportersinthekidneyperspectivesonspeciesdifferencesdiseasestatusandmoleculardocking AT zhengcai drugtransportersinthekidneyperspectivesonspeciesdifferencesdiseasestatusandmoleculardocking AT menghualiu drugtransportersinthekidneyperspectivesonspeciesdifferencesdiseasestatusandmoleculardocking AT menghualiu drugtransportersinthekidneyperspectivesonspeciesdifferencesdiseasestatusandmoleculardocking
_version_	1718405191341965312

Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking

Ejemplares similares